Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 11;54(4):dyaf086.
doi: 10.1093/ije/dyaf086.

The potential bias introduced into COVID-19 vaccine effectiveness studies at primary care level due to the availability of SARS-CoV-2 tests in the general population

Affiliations

The potential bias introduced into COVID-19 vaccine effectiveness studies at primary care level due to the availability of SARS-CoV-2 tests in the general population

Charlotte Lanièce Delaunay et al. Int J Epidemiol. .

Abstract

Background: With SARS-CoV-2 self-tests, persons with acute respiratory infections (ARI) can know their COVID-19 status. This may alter their decision to consult a general practitioner (GP), potentially biasing COVID-19 vaccine effectiveness (VE) studies. We explore bias mechanisms, simulate magnitude, and verify control methods.

Methods: We used directed acyclic graphs (DAGs) to illustrate the bias mechanisms. Based on the European primary care VEBIS multicentre test-negative design (TND) study, we simulated populations with varying true VE (20%-60%), proportions of persons with ARI self-testing (10%-30%), effect of COVID-19 vaccination on self-testing (1.5-2.5), and effect of self-test result on GP consultation (0.5-2). We performed 5000 runs per scenario, estimating VE among those consulting a GP. We calculated bias as true VE minus mean simulated VE, unadjusted and adjusted for self-testing, using logistic regression.

Results: DAGs suggested collider stratification bias if vaccination had an effect on self-testing and if self-test results affected GP consultation. Bias was -12% to 18% at 20% true VE, with the most extreme associations and 30% self-testing. With 60% true VE and 10%-20% self-testing, bias was lower. Bias was higher (-18% to 45%) if both positive and negative self-test results affected GP consultation. Adjusting for self-testing removed the bias.

Conclusions: Self-testing may bias COVID-19 VE TND studies in primary care if self-testing is high, particularly with low VE. We recommend primary care TND VE studies collect self-testing information to eliminate potential bias. Observational studies are needed to understand the relationship between vaccination, self-testing, and GP consultation, in these studies' source population.

Keywords: COVID-19; SARS-CoV-2; bias; primary health care; self-testing; vaccine effectiveness.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Directed acyclic graph representing hypothesized causal relationships between key variables in a test-negative design study of COVID-19 vaccine effectiveness at primary care level, in the absence of self-test use. The effect of interest is that of COVID-19 vaccination on SARS-CoV-2 infection.
Figure 2.
Figure 2.
Directed acyclic graph representing hypothesized causal relationships between variables in a test-negative design study of COVID-19 vaccine effectiveness at primary care level, in the context of self-test use, (A) without adjustment for self-testing and (B) with adjustment for self-testing. The effect of interest is that of COVID-19 vaccination on SARS-CoV-2 infection.
Figure 3.
Figure 3.
Difference between the estimated VE and the true VE (mean bias), in a simulated primary care-based test-negative design study, under different scenarios defined by key parameters, in the context of self-test use, without adjustment for self-testing. The first set of plots presents results of simulations varying the probability of GP consultation after a positive self-test result (expressed relatively to that among those not self-testing). The second set of plots presents results of simulations varying the probability of GP consultation after a negative self-test result (expressed relatively to that among those not self-testing). The probability of self-testing among the vaccinated is expressed relatively to that among the unvaccinated. 10% self-testing in the unvaccinated population equates to 17% overall, 20% self-testing to 34% overall, and 30% self-testing to 50% overall, under the assumption of a 2.5 probability ratio for self-testing among the vaccinated population. P, probability; Vacc, vaccinated.
Figure 4.
Figure 4.
Difference between the estimated VE and the true VE (mean bias), in a simulated primary care-based test-negative design study, with a probability ratio of self-testing of 2.5 among the vaccinated, 30% self-testing in the unvaccinated, and no effect of positive result on GP consultation, in the context of self-test use, with adjustment for self-testing. The probability of consultation after a negative self-test result is expressed relatively to that among those not self-testing.

References

    1. Supplisson O, Charmet T, Galmiche S et al. SARS-CoV-2 self-test uptake and factors associated with self-testing during Omicron BA.1 and BA.2 waves in France, January to May 2022. Euro Surveill 2023;28:2200781. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.18... - DOI - PMC - PubMed
    1. van Hagen C. The Association between SARS-CoV-2 Rapid Antigen Self-test Use and Healthcare Seeking Behaviour at Primary Care Level. Valencia, Spain: ESWI, 17 September 2023. https://s3.eu-central-1.amazonaws.com/eswi.org/downloads/ESWI2023_abstra... (6 September, date last accessed).
    1. Valenciano M, Ciancio B, I-MOVE Study Team. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill 2012;17:20281. - PubMed
    1. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31:2165–8. - PubMed
    1. Skowronski DM, Janjua NZ, Sabaiduc S et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis 2014;210:126–37. - PubMed

Substances